Legal and Policy Issues Currently Facing the Industry
Take a seat at the table as experts explore some of the current legal and policy issues impacting the generic drug and biosimilar supply chains–including drug shortages, legislative riders to user fee packages, biosimilars interchangeability, and inefficient practices and loopholes employed to delay market entry.
Legal and Policy
Topics:
-
-
-
- Legislative Outlook: Riders to the User Fee Packages and Other Topics
- Legislative Streamlining for Biosimilar Development: Biosimilar Red Tape Elimination Act & Expedited Access to Biosimilars Act
- Revising the National Drug Code Format and Drug Label Barcode Requirements
- The Future is Tagged: RFID Innovation across the Pharmaceutical Supply Chain
- U.S. Drug Shortages: Assessing Vulnerabilities and Informing Systemic Solutions
- Who Owns Biosimilar Education? Building a Lifelong Learning Framework for Healthcare Practitioners
-
-
*Topics are subject to change
Who should attend:
Possible job titles include:
Regulatory Affairs, Medical Affairs, Business Development, Program Management, Policy, Commercial Development, Scientific Affairs, Research Analyst
About GRx+Biosims
GRx+Biosims™ is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Get the latest information directly from Food and Drug Administration experts, understand the latest policy that impacts the industry and gain valuable insights to advance your professional development.
